Literature DB >> 26220729

Development and characterization of a clinical strain of Coxsackievirus A16 and an eGFP infectious clone.

Chenglin Deng1, Xiaodan Li, Siqing Liu, Linlin Xu, Hanqing Ye, Cheng-Feng Qin, Bo Zhang.   

Abstract

Coxsackievirus A16 (CA16) is one of the major causes of hand, foot, and mouth disease (HFMD) worldwide, which is a common illness that affects children. The frequent occurrence of HFMD outbreaks has become a serious public health problem in Asia. Therefore, it is important to understand the pathogenesis and replication of CA16. In this study, a stable infectious cDNA clone of an epidemic strain of Coxsackievirus A16 (CA16) was assembled, and subsequently a reporter virus (eGFP-CA16) was constructed by inserting the eGFP gene between the 5'-UTR and the N-terminus of VP4, with the addition of a 2A protease cleavage site (ITTLG) at its C-terminus. This was transfected into Vero cells to generate infectious recombinant viruses. The growth characteristics and plaque morphology, in vitro, in mammalian cells were found to be indistinguishable between the parental and recombinant viruses. Although the eGFP-CA16 showed smaller plaque size as compared to recombinant CA16, both were found to exhibit similar growth trends and EC50 of NITD008. In summary, this stable infectious cDNA clone should provide a valuable experimental system to study CA16 infection and host response. The eGFP-CA16 is expected to provide a powerful tool to monitor eGFP expression in infected cells and to evaluate the antiviral activity of potential antiviral agents in the treatment of CA16 infections.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26220729      PMCID: PMC8200862          DOI: 10.1007/s12250-015-3610-7

Source DB:  PubMed          Journal:  Virol Sin        ISSN: 1995-820X            Impact factor:   4.327


  23 in total

1.  Molecular evolution of the human enteroviruses: correlation of serotype with VP1 sequence and application to picornavirus classification.

Authors:  M S Oberste; K Maher; D R Kilpatrick; M A Pallansch
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

2.  Molecular characterization and complete genome analysis of human enterovirus 71 and coxsackievirus A16 from children with hand, foot and mouth disease in Thailand during 2008-2011.

Authors:  Jiratchaya Puenpa; Apiradee Theamboonlers; Sumeth Korkong; Piyada Linsuwanon; Chittima Thongmee; Susheera Chatproedprai; Yong Poovorawan
Journal:  Arch Virol       Date:  2011-09-07       Impact factor: 2.574

3.  Phenotypic and genomic characterization of human coxsackievirus A16 strains with distinct virulence in mice.

Authors:  Jian-Feng Han; Nan Yu; Yu-Xian Pan; Si-Jie He; Li-Juan Xu; Rui-Yuan Cao; Yue-Xiang Li; Shun-Ya Zhu; Yu Zhang; E-De Qin; Xiao-Yan Che; Cheng-Feng Qin
Journal:  Virus Res       Date:  2013-11-06       Impact factor: 3.303

4.  Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection.

Authors:  Yicun Cai; Qingwei Liu; Xulin Huang; Dapeng Li; Zhiqiang Ku; Yunfang Zhang; Zhong Huang
Journal:  Vaccine       Date:  2013-03-13       Impact factor: 3.641

5.  Characterization of a novel monoclonal antibody reactive against the N-terminal region of Enterovirus 71 VP1 capsid protein.

Authors:  Xiao Fang Lim; Qiang Jia; Vincent T K Chow; Jimmy Kwang
Journal:  J Virol Methods       Date:  2012-12-07       Impact factor: 2.014

6.  Development and characterization of a stable eGFP enterovirus 71 for antiviral screening.

Authors:  Baodi Shang; Chenglin Deng; Hanqing Ye; Wenbo Xu; Zhiming Yuan; Pei-Yong Shi; Bo Zhang
Journal:  Antiviral Res       Date:  2012-12-22       Impact factor: 5.970

7.  A neonatal mouse model of coxsackievirus A16 for vaccine evaluation.

Authors:  Qunying Mao; Yiping Wang; Rong Gao; Jie Shao; Xin Yao; Shuhui Lang; Chao Wang; Panyong Mao; Zhenglun Liang; Junzhi Wang
Journal:  J Virol       Date:  2012-09-05       Impact factor: 5.103

8.  Median effective effect-site concentration of sufentanil for wake-up test in adolescents undergoing surgery: a randomized trial.

Authors:  Cheng-Hua Zhang; Wei-Qing Ma; Yun-Li Yang; Hui-Ming Wang; Fa-Tuan Dong; Zhang-Xiang Huang
Journal:  BMC Anesthesiol       Date:  2015-03-08       Impact factor: 2.217

9.  Circulating HFMD-associated coxsackievirus A16 is genetically and phenotypically distinct from the prototype CV-A16.

Authors:  Wei Wei; Haoran Guo; Jingliang Li; Sangsang Ren; Zhenhong Wei; Wanguo Bao; Xiaoming Hu; Ke Zhao; Wenyan Zhang; Yulai Zhou; Fei Sun; Richard Markham; Xiao-Fang Yu
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

10.  Enterovirus genotypes causing hand foot and mouth disease in Shanghai, China: a molecular epidemiological analysis.

Authors:  Menghua Xu; Liyun Su; Lingfeng Cao; Huaqing Zhong; Niuniu Dong; Jin Xu
Journal:  BMC Infect Dis       Date:  2013-10-22       Impact factor: 3.090

View more
  3 in total

1.  2C Proteins of Enteroviruses Suppress IKKβ Phosphorylation by Recruiting Protein Phosphatase 1.

Authors:  Qian Li; Zhenhua Zheng; Yan Liu; Zhenfeng Zhang; Qingshi Liu; Jin Meng; Xianliang Ke; Qinxue Hu; Hanzhong Wang
Journal:  J Virol       Date:  2016-04-29       Impact factor: 5.103

2.  The Establishment of Infectious Clone and Single Round Infectious Particles for Coxsackievirus A10.

Authors:  Min Wang; Jingjing Yan; Liuyao Zhu; Meng Wang; Lizhen Liu; Rui Yu; Ming Chen; Jingna Xun; Yuling Zhang; Zhigang Yi; Shuye Zhang
Journal:  Virol Sin       Date:  2020-03-06       Impact factor: 4.327

3.  Construction of a recombinant rhinovirus accommodating fluorescent marker expression.

Authors:  Mingyuan Han; Charu Rajput; Joanna L Hinde; Qian Wu; Jing Lei; Tomoko Ishikawa; J Kelley Bentley; Marc B Hershenson
Journal:  Influenza Other Respir Viruses       Date:  2018-09-06       Impact factor: 4.380

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.